Latest / Decera Clinical Education Oncology Podcast
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach
In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:
Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer
Results of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant disease
How R-DXd may be incorporated into the treatment paradigm
Other investigational CDH6-targeting ADCs: CUSP06, SIM0505
Presenters:
Kathleen N. Moore, MD, MS, FASCO
Deputy Director and Cancer Therapeutics Co-Lead
Stephenson Cancer…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.